USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Aug 26, 2022 (est) | Jun 30, 2022 | $-0.10 | $-0.20 | $-0.25 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Aug 26, 2022 (est) | Jun 30, 2022 | $0.00 | $0.00 | $0.00 |
Biondvax Pharmaceuticals's next estimated earnings date (based on same quarter last year's date) is Aug 26, 2022 for the fiscal quarter ending Jun 30, 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Sep 2022 | 2 | $-0.11 | $-0.21 | $-0.01 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 2 | $-0.41 | $-0.81 | $-0.02 |
| Dec 2023 | 2 | $-0.45 | $-0.89 | $-0.02 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Sep 2022 | 0 / 0 | $-0.11 | $-0.17 | $-0.17 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 0 | $-0.41 | $-0.35 | $-0.35 |
| Dec 2023 | 1 / 0 | $-0.45 | $-0.38 | $-0.38 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Sep 2022 | 2 | $0.00 | $0.00 | $0.00 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 2 | $0.00 | $0.00 | $0.00 |
| Dec 2023 | 2 | $0.00 | $0.00 | $0.00 |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Jun 1, 2022 | Mar 2022 | $-0.10 | $-0.20 | -100.00% |
| Mar 28, 2022 | Dec 2021 | $-0.08 | $-0.27 | -237.50% |
| Nov 30, 2021 | Sep 2021 | - | $-0.20 | - |
| Aug 26, 2021 | Jun 2021 | - | $-0.25 | - |
| May 13, 2021 | Mar 2021 | - | $-0.26 | - |
| Jan 28, 2021 | Dec 2020 | $-0.01 | $-0.18 | -1745.00% |
| Dec 31, 2020 | Sep 2020 | - | $-0.39 | - |
| Aug 20, 2020 | Jun 2020 | $-0.01 | $-1.14 | -11300.00% |
| Jun 12, 2020 | Mar 2020 | $-0.01 | $-0.10 | -900.00% |
| Nov 26, 2019 | Sep 2019 | $-0.03 | $-0.80 | -2566.67% |
| Aug 28, 2019 | Jun 2019 | $-0.02 | $-2.04 | -10100.00% |
| Apr 30, 2019 | Mar 2019 | $-0.01 | $-0.05 | -400.00% |
| Dec 31, 2018 | Dec 2018 | $-0.01 | $-0.05 | -400.00% |
| Nov 13, 2018 | Sep 2018 | $-0.01 | $-0.00 | 73.00% |
| Aug 22, 2018 | Jun 2018 | - | $-1.09 | - |
| May 1, 2018 | Mar 2018 | - | $-0.01 | - |
| Nov 28, 2017 | Sep 2017 | $-0.19 | $-0.12 | 36.84% |
| Aug 31, 2017 | Jun 2017 | - | $-0.78 | - |
| Apr 28, 2017 | Mar 2017 | $-0.01 | $-0.18 | -1700.00% |
| Nov 28, 2016 | Sep 2016 | $-0.01 | $-0.01 | - |
| Aug 18, 2016 | Jun 2016 | - | $-0.20 | - |
| Apr 27, 2016 | Mar 2016 | $-0.09 | $-0.25 | -177.78% |
| Nov 9, 2015 | Sep 2015 | $-0.11 | $0.01 | 109.09% |
| Aug 10, 2015 | Jun 2015 | $-0.12 | $-0.14 | -16.67% |
| May 15, 2015 | Mar 2015 | - | $-0.35 | - |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 28, 2022 | Dec 2021 | $-0.42 | $-0.97 | - |
| Jan 28, 2021 | Dec 2020 | $0.00 | $-4.70 | - |
| Dec 31, 2018 | Dec 2018 | $-0.09 | $-3.18 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Jun 1, 2022 | Mar 2022 | $0.00 | $0.00 | - |
| Mar 28, 2022 | Dec 2021 | - | $0.00 | - |
| Nov 30, 2021 | Sep 2021 | - | $0.00 | - |
| Aug 26, 2021 | Jun 2021 | - | $0.00 | - |
| May 13, 2021 | Mar 2021 | - | $0.00 | - |
| Jan 28, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Dec 31, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Aug 20, 2020 | Jun 2020 | - | $0.00 | - |
| Jun 12, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Nov 26, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 28, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| Apr 30, 2019 | Mar 2019 | $0.00 | $0.00 | - |
| Dec 31, 2018 | Dec 2018 | - | $0.00 | - |
| Nov 13, 2018 | Sep 2018 | - | $0.00 | - |
| Aug 22, 2018 | Jun 2018 | - | $0.00 | - |
| May 1, 2018 | Mar 2018 | $0.00 | $0.00 | - |
| Nov 28, 2017 | Sep 2017 | - | $0.00 | - |
| Aug 31, 2017 | Jun 2017 | - | $0.00 | - |
| Apr 28, 2017 | Mar 2017 | - | $0.00 | - |
| Nov 28, 2016 | Sep 2016 | - | $0.00 | - |
| Aug 18, 2016 | Jun 2016 | - | $0.00 | - |
| Apr 27, 2016 | Mar 2016 | - | $0.00 | - |
| Nov 9, 2015 | Sep 2015 | - | $0.00 | - |
| Aug 10, 2015 | Jun 2015 | - | $0.00 | - |
| May 15, 2015 | Mar 2015 | - | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 28, 2022 | Dec 2021 | $0.00 | $0.00 | - |
| Jan 28, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Dec 31, 2018 | Dec 2018 | $0.00 | $0.00 | - |
BVXV's next estimated earnings date (based on same quarter last year's report date) is Aug 26, 2022 for the fiscal quarter ending Jun 30, 2022.
Biondvax Pharmaceuticals's previous earnings date was Jun 1, 2022 for its fiscal quarter ended Mar 31, 2022.
BVXV's earnings per share (EPS) was $-0.20, missing the consensus analysts forecast of $-0.10 by -100.00%.
The EPS was higher than the previous fiscal quarter (Dec 2021) by -25.93%, and higher than the same period a year before (Mar 2021) by -22.09%.
Revenues were $0.00.
The company reported a net income of $-9.42M.BVXV ended the quarter with $71.57M in total debt, an increase of 2.63% compared to the previous quarter, and an increase of 3.78% compared to the same quarter a year before.
Biondvax Pharmaceuticals's previous annual earnings date was Mar 28, 2022 for its fiscal year ended Dec 31, 2021.
BVXV's earnings per share (EPS) was $-0.97.
Revenues were $0.00.
The company reported a net income of $-39.98M.
Biondvax Pharmaceuticals reported a free cash flow of $-24.91M for its fiscal year, compared to $-78.67M a year ago.
The company ended the fiscal year with $69.74M in total debt, an increase of 3.83% compared to the previous year.
